31 October 2022

A promising drug

The new drug has shown impressive results in the treatment of liver cancer

Svetlana Maslova, Hi-tech+

Scientists have presented promising results of the first phase of clinical trials of an experimental drug for the treatment of patients with resistant liver cancer. In some volunteers, the tumor decreased by at least 30%.

In the pilot phase of research, about which he writes Medical Express, involved 12 patients with liver cancer who had previously received three different lines of anti-cancer therapy. As a result of standard treatment, it was not possible to stop the spread of the disease. As part of the experimental treatment, they received intravenously the drug NMS-01940153E, which was administered in an increasing dose course.

NMS-01940153E is aimed at suppressing the MPS1 enzyme, which is overexpressed in various types of tumors, including liver cancer. MPS1 plays a key role in regulating the processes of cell division and growth, so violations in its work can lead to the development of malignant neoplasm.

The scientists noted promising therapeutic results, as well as a manageable treatment safety profile. In two patients, the tumor decreased by at least 30% within two and nine months. Meanwhile, after about six months and eleven months, respectively, the tumor showed signs of growth again. In two more patients, the development of the disease completely stopped — the tumor did not decrease in size, but stopped growing.

"Since each of the patients had three previous failures before NMS-01940153E, the response to our new treatment looks very promising, especially in resistant cancer," commented the author of the work Maria Reig.

Currently, the second phase of research has already been launched, which also involves patients who have not been helped by surgery and other standard methods of treatment. This stage will be completed at the end of 2024 and will allow us to evaluate the optimal safe dosage and administration scheme of the drug.

Recently, other scientists presented the results of another experimental therapy in the fight against cancer. It is aimed at suppressing a common cancer gene that plays a key role in the development and progression of many types of tumors.

Portal "Eternal youth" http://vechnayamolodost.ru

Found a typo? Select it and press ctrl + enter Print version